Cargando…
Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial
BACKGROUND: Alcohol use disorder (AUD) is a chronic and relapsing condition for which current pharmacological treatments are only modestly effective. The development of efficacious medications for AUD remains a high research priority with recent emphasis on identifying novel molecular targets for AU...
Autores principales: | Burnette, Elizabeth M., Baskerville, Wave-Ananda, Grodin, Erica N., Ray, Lara A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488583/ https://www.ncbi.nlm.nih.gov/pubmed/32912290 http://dx.doi.org/10.1186/s13063-020-04670-y |
Ejemplares similares
-
Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial
por: Grodin, Erica N., et al.
Publicado: (2021) -
Embedding comprehensive smoking cessation programs into community clinics: study protocol for a cluster-randomized controlled trial
por: Baskerville, Wave-Ananda, et al.
Publicado: (2022) -
A novel human laboratory model for screening medications for alcohol use disorder
por: Ho, Diana, et al.
Publicado: (2020) -
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
por: Burnette, Elizabeth M., et al.
Publicado: (2022) -
Bangpungtongsung-san for patients with major depressive disorder: study protocol for a randomized controlled phase II clinical trial
por: Kim, Yunna, et al.
Publicado: (2023)